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a b s t r a c t
Background: Inhibitors of the phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamy-
cin (mTOR) pathway are currently in clinical trials. In addition to antiproliferative and proapoptotic
effects, these agents also diminish tumor hypoxia. Since hypoxia is a major cause of resistance to radio-
therapy, we sought to understand how it is regulated by PI3K/mTOR inhibition.
Methods: Whole cell, mitochondrial, coupled and uncoupled oxygen consumption were measured in can-
cer cells after inhibition of PI3K (Class I) and mTOR by pharmacological means or by RNAi. Mitochondrial
composition was assessed by immunoblotting. Hypoxia was measured in spheroids, in tumor xenografts
and predicted with mathematical modeling.
Results: Inhibition of PI3K and mTOR reduced oxygen consumption by cancer cell lines is predominantly
due to reduction of mitochondrial respiration coupled to ATP production. Hypoxia in tumor spheroids
was reduced, but returned after removal of the drug. Murine tumors had increased oxygenation even
in the absence of average perfusion changes or tumor necrosis.
Conclusions: Targeting the PI3K/mTOR pathway substantially reduces mitochondrial oxygen consump-
tion thereby reducing tumor hypoxia. These alterations in tumor hypoxia should be considered in the
design of clinical trials using PI3K/mTOR inhibitors, particularly in conjunction with radiotherapy.
! 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 111 (2014) 72–80 This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
3.0/).
Genetic alterations that lead to aberrant activation of the PI3K
and mTOR pathways are among the most frequent in cancers of
all types [8,40]. PI3K/mTOR pathway signaling promotes a plethora
of oncogenic cellular functions including growth and cell survival.
As a result, a variety of pharmacologic agents have been developed
to inhibit this pathway and are entering clinical trials [25].
In addition to reducing tumor proliferation and survival, we and
others have shown that inhibitors of the PI3K pathway greatly
diminish tumor hypoxia [14,38,53], a characteristic feature of solid
tumors which correlates with poorer prognosis, increased metasta-
sis and resistance to therapeutic intervention, particularly radio-
therapy (XRT) [18,33,34]. A variety of strategies to increase tumor
oxygenation have been proposed in order to improve the outcome
of XRT, including the inhalation of hyperoxic gases [20–23,42],
and vascular normalization [10,19,41]. Poor local perfusion is a
major contributor to hypoxia, resulting from the disorganized
vasculature, increased interstitial pressures and transient vascular
closures commonly found in cancer [50]. Inhibition of PI3K
signaling results in improved vascular structure and perfusion
[14,38], suggesting that vascular normalization plays a role in the
observed reoxygenation. However, potential contributions of
alterations in oxygen consumption have not been determined.
Mathematical modeling of the roles of supply and demand in tumor
oxygenation suggests that reduction of hypoxia is more likely to be
accomplished by decreasing tumor oxygen consumption than by
improvement of vascular supply [45].
Consistent with this idea, Gallez and colleagues have shown
that treatment of some murine tumors with inhibitors of the
Epidermal Growth Factor Receptor (EGFR) or with AsO3 leads to
decreased O2 consumption and hence decreased hypoxia in exper-
imental tumors correlating with enhanced efficacy of XRT [3,12].
The effects of inhibiting PI3K and mTOR on O2 consumption and
tissue oxygenation however, have not been similarly explored.
Here we report that pharmacological and genetic inhibition of
PI3K and/or mTOR leads to diminished O2 consumption in a panel
of cell lines from different primary tumors. Using spheroid and
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in vivo models, we found that tissue hypoxia was reduced even in
the absence of vascular remodeling by pharmacological inhibition
of PI3K/mTOR.
Methods
In vitro studies
The cell lines tested FaDu (human nasopharyngeal), EMT6
(mouse mammary carcinoma), HCT116 (human colorectal) and
U87 (human glioma) were chosen because they form spheroids
of sufficient size (!400–500 lm diameter) to become hypoxic.
Spheroids generated using the liquid overlay technique [9] were
treated 6 days after initiation.
Treatments
BEZ235 and BKM120 (Novartis Pharmaceuticals) and AZD8055
(#CT-A8055, ChemieTek) were dissolved in 0.1% DMSO. Control
groups were treated with equal amounts of DMSO.
Cell transfections were performed by reverse transfection with
Interferin (PolyPlus) using 5 nM short interfering RNA (siRNA) oli-
gonucleotides for PI3K110a (#L-003018), p85b (#L-003021),
mTOR (#L-003008) and non-targeting (#D-001810) from Dharma-
con RNAi Technologies. Doses in tissue culture were chosen based
on the lowest concentration to reduce pAKT repeatably and by at
least approximately 3-fold.
Immunoblotting
Antibodies were: pAKT (Ser-573 #9271, 1:1000), pmTOR (Ser-
2448 #2971, 1:500), pS6 ribosomal protein (Ser235/236 #4856,
1:1000), all Cell Signalling Technology in 5% Bovine Serum Albu-
min (BSA); Actin (mAb clone AC-15 #A1978, Sigma, 1:20,000 in
5% milk); OXPHOS complexes (#MS601, Mitosciences, 1:500 in
milk); citrate synthase (#CISY-11A, Alpha Diagnostic, 1:500 in
milk).
Oxygen consumption
Cells were seeded in 96-well plates from Seahorse Biosciences
prior to treatment with inhibitors (24 h) or siRNA (48 h). One hour
prior to the assay, culture medium was replaced with modified
DMEM (Seahorse Bioscience) supplemented with 5 mM sodium
pyruvate, 4 mM glutamine, (pH 7.4). The rate of oxygen consump-
tion (OCR) was measured at 37 !C using an XF96 extracellular ana-
lyzer (Seahorse Bioscience). Four measurements were taken before
and three after each sequential injection of oligomycin (1 lM), FCCP
(0.8 lM) and rotenone and antimycin A (both 1 lM). Plates were
fixed with 4% paraformaldehyde (pFA) and stained with Hoechst
33342 (H3570, Invitrogen). Cell number was proportional to fluo-
rescence (Ex 380 nM and Em 450 nM). The OCR linked to coupled
respiration was obtained by subtracting OCR after the addition of
oligomycin from basal OCR. OCR after addition of themitochondrial
uncoupler FCCP reflected the maximal respiratory rate. Non-mito-
chondrial respiration was defined as the rate after rotenone/anti-
mycin A application and was subtracted from the basal OCR to
determine the mitochondrial OCR. ‘‘To account for variations in cell
number brought about by drug-induced effects on proliferation or
cell death, all raw OCR values were normalized to cell density mea-
surements as determined by Hoechst fluorescence, on a well-by-
well basis. At the end of the assay, plates were fixed with 4% para-
formaldehyde (pFA), and stained with Hoechst 33342 (2 lg/ml,
H3570, Invitrogen) prior to measuring fluorescence (Ex 380 nM
and Em 450 nM). The effect of treatment on cell density with
BEZ235 or BKM120 varied across cell lines (Supplemental Fig. 1A).
Isolation of mitochondrial-enriched fraction
Mitochondria were isolated as previously described [16,51].
2 " 107 cells were centrifuged at 750g for 5 min at 4 !C,
resuspended in cold PBS, centrifuged and resuspended in isolation
buffer (containing 10 mM Tris–HCl, 0.32 M sucrose, 0.1 mM EGTA,
and 1:100 Halt Protease Inhibitor Cocktail. After 10 freeze/thaw cy-
cles (#70 !C for 3 m and 37 !C for 2 min), the homogenates were
centrifuged at 700g for 10 min to remove the nuclei and unbroken
cells. Supernatants were centrifuged at 12,000g for 10 min to sep-
arate the mitochondria and cytosol.
Spheroids
To quantify hypoxia, spheroids were incubated with 200 lM
EF5 (2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)
acetamide), a gift from Cameron Koch’s lab) for 6 h at 37 !C, prior
to overnight fixation in 4% pFA in PBS and preservation in 30% su-
crose in PBS at 4 !C. 8 lm sections were incubated overnight at 4 !C
with the EF5 Cy3-conjugated monoclonal antibody ELK3-51
(www.hypoxia-imaging.org) and counterstained with Hoechst
33342. Images were acquired with a Nikon Eclipse 90i with a Ham-
amatsu ORCA-ER camera. A mask was created for each spheroid
using the Hoechst image, prior to measuring the average pixel
intensity per spheroid in the background-subtracted EF5 image
using ImageJ [1].
To assess signaling inhibition in spheroids, sections were
stained with anti-pAKT antibody using ImmPRESS™ reagent kit
(MP-7401, VectorLabs) and DAB Peroxidase substrate kit (SK-
4100, VectorLabs). Images acquired with a Nikon Eclipse E800
were analyzed for 3,30-Diaminobenzidine (DAB)-positive pixels
semi-automatically using a method described previously [6].
Statistical analysis
Quantitative data were expressed as means ± 95% Confidence
Interval. One-way ANOVAs, followed by the Bonferroni post-test,
were used to assess the differences among various treatments with
Prism 5 (GraphPad Software Inc.), unless otherwise stated.
Mathematical modeling
For simulation of in vivo O2 consumption, 2D vascular networks
were generated stochastically [37], using vessel parameter distri-
butions (vessel length, diameter and branching angle) obtained
from ex vivo data [14]. The resulting coupled blood flow and O2
transport problem was solved using code available via Dr. Se-
comb’s website (www.physiology.arizona.edu/people/secomb/
greens). A representative base O2 consumption rate of 1.5 cm3/
100 cm3/min was used [46].
In vivo studies
All animal experiments were carried out in accordance with UK
Home Office regulations. FaDu cells bearing a HRE-luc reporter
(Cignal Lenti HIF Reporter luciferase (SABiosciences)), for hypoxia
were described and validated previously [38]. 1 " 106 cells were
inoculated subcutaneously in athymic nude mice. Mice were di-
vided into cohorts of n = 4 mice per cohort. Drug administration
by oral gavagewas initiated once tumors reached 100 mm3 volume,
as determined using calipers. Tumors were treated for 7 days with
BEZ235 at 0, 20 or 30 mg/kg in NMP/PEG300 (Novartis Pharmaceu-
ticals, Basel, Switzerland). Decreases in hypoxia were seen at 3 days
with maximal effects by 5–7 days. We failed to observe effects at
earlier times. Thus we used 7 days for these experiments. Imaging
of hypoxia and perfusion was carried out as previously described
[38]. Before sacrifice EF5 was administered as previously described
[38]. Tumor tissue was fixed and stained for EF5 and Ki-67. Images
were acquired using a Nikon Eclipse E800 microscope with a Nikon
DMX1200 digital camera and measured with ImageJ.
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Results
PI3K/mTOR inhibition reduced tumor cell oxygen consumption
The O2 consumption rate (OCR) of cancer cell monolayers (nor-
malized to cell number) was reduced after 24 h treatment with the
Class I PI3K inhibitor BKM120 or with the dual PI3K/mTOR
inhibitor BEZ235 (Fig. 1A, P < 0.01, one-way ANOVA and Supple-
mental Fig. 1B). A trend for reduced OCR was evident within 5 h
of treatment with either inhibitor although this was not uniformly
significant (Supplemental Fig. 1C). Functional inhibition of PI3K
was demonstrated by dose-dependent reduction in AKT phosphor-
ylation at 24 h (Fig. 1C). Both drugs also reduced the phosphoryla-
tion of mTOR and S6. BEZ235 is a direct inhibitor of mTOR.
Fig. 1. Inhibition of PI3K and mTOR activities reduces oxygen consumption in vitro. (A) Effect of dual PI3K/mTOR inhibitor BEZ235 and single Class I PI3K inhibitor BKM120 on
cellular oxygen consumption rate (OCR). FaDu, EMT6, HCT116 and U87 cells were treated as indicated for 24 h. Total cellular oxygen consumption rate (OCR) was calculated
in n = 12 wells. Data shown are representative of three independent experiments. (B) Immunoblotting confirmed reduction in signaling through the PI3K/mTOR pathway in
monolayers treated with BEZ235 or BKM120 for 4 h (12 h and 24 h for HCT116 and U87 respectively). (C) Treatment for 24 h with the mTOR inhibitor AZD8055 decreased
OCR. (D) Immunoblotting for pS6 confirmed AZD8055 reduced mTOR signaling. (E) Immunoblots for mTOR, the PI3K subunits p110a and p85b, and Actin in FaDu cells
transfected with non-targeting (NT) and PI3K, mTOR siRNA for 3 days, demonstrate that target protein levels were reduced. (F) Immunoblots for pAKT and pmTOR in
transfected cells show reduced signaling through the PI3K/mTOR pathway. (G) FaDu cells transfected with PI3K p110a, p85b or mTOR siRNA exhibit reduced mitochondrial
OCR compared with those transfected with NT siRNA. All data points represent mean ± 95% Confidence Interval. One-way ANOVAs were performed with Bonferroni-corrected
post t-tests comparing treated to DMSO-treated control samples. ⁄P < 0.01. Data shown are representative of three independent experiments.
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However since mTOR is also a downstream target of PI3K, the de-
crease in pmTOR and pS6 seen with BKM120, a specific PI3K inhib-
itor is not unexpected. Thus the use of the specific PI3K inhibitor
BKM120 does not preclude mTOR as a target. mTOR can also feed-
back onto PI3K and AKT pathways. The OCR in cells treated with
the direct mTOR inhibitor AZD8055 was also reduced in a dose-
dependent fashion (Fig. 1C and D). Treatment with rotenone and
antimycin A, which block mitochondrial electron transport, inhib-
ited the O2 consumption by these cells (FaDu 82.9%; EMT6 91.1%;
HCT116 79%; U87 75%) showing that mitochondrial respiration ac-
counted for the preponderance of O2 consumption. Thus treatment
with PI3K/mTOR inhibitors diminished the mitochondrial O2 con-
sumption in a variety of cancer cells.
In addition, we reduced signaling in FaDu cells by genetic means
(Fig. 1E and F). RNAi against PI3K 85b (regulatory domain) and PI3K
110a (catalytic domain) reduced their respective protein levels and
depressed signaling as measured by pAKT and pS6 levels. RNAi
against mTOR reduced its protein levels and also depressed the sig-
naling through S6. O2 consumption in PI3K andmTOR-silenced cells
was reduced by 25–30% compared to the non-targeted control
(Fig. 1G). Thus genetic interferencewith the PI3K signaling pathway
also reduced O2 consumption as did pharmacological inhibition.
The PI3K/mTOR pathway is a promoter of glycolytic metabo-
lism [13,52]. In the cell lines tested, treatment with BKM120 re-
duced glycolysis. However, BEZ235 inhibited glycolysis in some
cell lines, but not in others (Supplementary Fig. 1D). Because
mitochondrial oxygen consumption can be limited by substrate
availability through glycolysis, glucose-free medium supple-
mented with pyruvate and glutamine was used for the above
OCR measurements.
PI3K/mTOR inhibition reduce mitochondrial function, not protein
We examined the possibility that a reduction in mitochondrial
mass might contribute to decreased O2 consumption. However,
the levels of citrate synthase, a component of the Krebs cycle fre-
quently used to monitor mitochondrial mass, remained unchanged
after treatment with either inhibitor (Fig. 2A and Supplementary
Fig. 2A). Levels of electron transport chain (ETC) complexes I, IV
and V (ATP synthase) increased in the mitochondrial fraction of
FaDu cells treated with BEZ235 or BKM120 compared to the con-
trol (Fig. 2B), confirming that the mitochondrial amounts were
not reduced.
We next looked at the effect of BEZ235 and BKM120 on mito-
chondrial bioenergetics. In a normally functioning cell, the rate of
cellular O2 consumption (as shown in Fig. 1A) is determined by
the activity of the electron transport chain (ETC) and the rate of
ATP production, with these processes ‘coupled’ via the proton gra-
dient (Fig. 2C). In addition to this, proton leakage and non-mito-
chondrial also contribute. To assess the specific contributions of
ATP synthesis and ETC activity to altered O2 consumption, we com-
pared respiration in both the coupled and uncoupled states
through sequential addition of oligomycin (an ATP synthase inhib-
itor) and FCCP (which dissipates the proton gradient) (Fig. 2D).
Coupled respiration was reduced by BEZ235 or BKM120 treatment
in all cell lines (Fig. 2E). However, as coupled respiration is depen-
dent on the supply of electrons from the ETC, this does not in itself
show that the reduction is dependent on ATP synthase activity.
Hence it is necessary to also consider uncoupled respiration, which
reflects ETC activity. Treatment with BEZ235 or BKM120 reduced
uncoupled respiration in the human cells lines (FaDu, HCT116
and U87), although the effect was smaller than that observed for
coupled respiration (Fig. 2F). Thus both coupled and uncoupled
respiration are inhibited by PI3K/mTOR inhibition.
Decreased oxygen consumption corresponds to a substantial
improvement in 3D oxygenation
To evaluate whether the results in monolayers could translate
to a 3D tissue environment, we examined hypoxia within spher-
oids. Inhibition of PI3K in FaDu and EMT6 spheroids was demon-
strated by reduction of pAKT staining after drug treatment
(Fig. 3A and B). Spheroids of 450–500 lm diameter were treated
for 24 or 48 h with either DMSO, BEZ235 (50 nM) or BKM120
(5 lM). Hypoxia that was evident in the control spheroids, as indi-
cated by EF5 staining, was reduced in spheroids treated with either
BEZ235 or BKM120 (Fig. 3C and D). These spheroids were smaller
than the controls (Supplementary Fig. 3A), suggesting proliferation
was affected by the inhibitors. As EF5 binds only in viable cells,
there was the possibility that cell death accounted for the reduc-
tion in signal. To examine this possibility, the spheroids were re-
turned to drug-free medium after 24 h of drug treatment.
Hypoxia recurred, demonstrating viability with the exception of
BKM120-treated FaDu spheroids. (Fig. 3C and E) (p < 0.01, two-
way ANOVA). Dose-dependent reductions in hypoxia were also ob-
served in HCT116 spheroids (Supplementary Fig. 3B). Thus de-
creased O2 consumption due to PI3K/mTOR inhibition leads to
decreased hypoxia in spheroids.
Reduction in hypoxia in treated tumors is consistent with impaired
oxygen consumption
The findings using spheroids presented above support the
hypothesis that reduction of oxygen consumption due to PI3K/
mTOR inhibition would result in a reduction of tumor hypoxia
in vivo. Additionally since spheroids are avascular, their use by-
passes the complexities of the tumor vasculature. To evaluate the
effect that reduced O2 consumption might have in the context of
abnormal vasculature, we used a mathematical modeling approach
developed by Secomb et al. [46]. 2D and 3D vascular networks
were generated in silico, derived from serial confocal images of
xenografts from the FaDu cell line [14]. Simulations of blood flow
through these vascular networks were combined with factors for
the rate of O2 diffusion and O2 consumption by the surrounding tis-
sue. Fig. 3F and G show oxygen distributions in one such vascular
network using two different rates of O2 consumption (maximum
and 55% of maximum, the latter observed in FaDu cells treated
with 100 nM BEZ235). Using this model we calculated the mean
hypoxic fraction from 10 different vascular networks observed in
FaDu tumors across a range of decrements in O2 consumption rates
(Fig. 3H). A decrease of 20% in oxygen consumption would be pre-
dicted to decrease the mean hypoxic fraction by one-third, based
on this model. Thus smaller reductions of O2 consumption than
the maximal observed in the monolayer would be predicted to
be medically significant.
To test our predictions, we treated mice bearing FaDu HRE-Luc
xenografts with BEZ235 at two different doses (20 mg/kg and
30 mg/kg). Both doses significantly reduced the luciferase signal
compared to the untreated tumors (Fig. 4A). Reduction in hypoxia
was confirmed through EF5 staining (Fig. 4B). We have previously
demonstrated that administration of 20 mg/kg BEZ235 results in a
greater density of normalized blood vessels and increased perfu-
sion in FaDu xenograft [14]. However PI3K inhibition with
BEZ235 or other drugs at higher doses has been reported to lead
to blood vessel destruction in tumors [14,17,24]. Tumors treated
with 30 mg/kg BEZ235 had no increase in perfusion compared to
the control (Fig. 4C), but still demonstrated a substantial reduction
in hypoxia. Both doses led to greater than 5-fold reduction of pAKT
or pS6 staining (Fig. 4D). However the lower dose did not reduce
proliferation of the tumor cells while the higher dose had a strong
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antiproliferative effect on the tumor cells without noticeable histo-
logical evidence of necrosis (Fig. 4D, quantified in Fig. 4E). Reduced
proliferation at the higher, but not the lower, dose was reflected in
growth curves (Supplemental Fig. 4). Both doses resulted in de-
creased hypoxia. Treatment of mice with tumors with BEZ235 at
the higher dose led to decreased hypoxia despite no change in
Fig. 2. Decrease in oxygen consumption correlates with a decline in mitochondrial function. (A) Mitochondrial mass in FaDu and EMT6 cells treated for 24 h with BEZ235 and
BKM120 was unaffected, as confirmed by immunoblotting for citrate synthase. (B) Levels of the electron transport chain (ETC) complexes II, III and V (F0F1-ATPase) increased
in FaDu mitochondria treated with BEZ235 and BKM120 compared to the DMSO-treated control (Ctl). (C) The functionality of mitochondria is dependent on the constant
cycling of protons (H+) between the intermembrane space and the mitochondrial matrix. The inner and outer mitochondrial membranes (IMM and OMM) act as barriers to
H+ transport. Movement of protons into the intermembrane space by the ETC complexes results in a mitochondrial membrane potential (MMP) which is relieved by F0F1-
ATPase during the generation of ATP. Alterations to the MMP indicate a change in this flux. Mitochondrial function can be disrupted by the addition of (1) FCCP, which
dissipates the H+ gradient and the MMP, uncoupling respiration from ATP production and enabling it to occur at its maximal rate; (2) Oligomycin, which inhibits F0F1-ATPase,
enables calculation of ATP-dependent (coupled) respiration. (D) Coupled and uncoupled respiration were determined in cells to which either FCCP or oligomycin
(respectively) had been added. Subtraction of the post-oligomycin OCR from the basal OCR gives coupled respiration. Uncoupled respiration is determined by subtracting the
post-rotenone (non-mitochondrial) OCR from the post-FCCP OCR. (E and F) Coupled respiration was significantly reduced in all cell lines after 24 h treatment with BEZ235 or
BKM120 compared to the DMSO-treated control. The effect of treatment with BEZ235 or BKM120 on uncoupled respiration varied across cell lines. All data points represent
mean ± 95% Confidence Interval in n = 12 wells. Data shown are representative of three independent experiments. One-way ANOVAs were performed with Bonferroni-
corrected post t-tests comparing treated to DMSO-treated control samples. ⁄P < 0.01.
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Fig. 3. Hypoxia is reduced in a 3D spheroid model and is predicted to decline in vivo. (A) EMT6 and FaDu spheroids were treated for 24 h with BEZ235 or BKM120, prior to
fixation and sectioning. Sections were DAB-stained for pAKT (Ser473) expression. Representative images are shown for BEZ235 (50 nM) and BKM120 (5 lM). (B) The
percentage of DAB-positive pixels in the viable region of the spheroid was reduced with all treatments. (C) Spheroids were treated with 50 nM BEZ235 or 5 lM BKM120 for
24 h, 48 h or 24 h followed by 24 h incubation in drug-free medium (24 h + wash). Hypoxia was assessed by staining central spheroid sections for EF5 (red) with Hoechst as a
counterstain (blue). Data shown are representative of two independent experiments, n = 10 spheroids. (D) Mean EF5 fluorescence in spheroids treated for 24 h was reduced in
both cell lines tested. (E) To assess whether hypoxia was recoverable, mean EF5 fluorescence in spheroids treated for 24 h was compared with that in spheroids treated for
either 48 h or 24 h followed by the 24 h wash in drug-free medium. In cells treated with BEZ235, the 24 h wash period led to a return of the hypoxia signal. (F and G)
Simulated distribution of oxygen partial pressure (mmHg) in a representative 1497 lm ! 1482 lm vascular network derived from ex vivo samples where oxygen
consumption was either 100% (F) or 55% (G) of base level. Highly oxygenated regions are in red, scaling down to poorly oxygenated regions in blue. (H) Average hypoxic
fraction (defined as <10 mmHg) calculated across 10 example networks as in F as a function of varying oxygen consumption. All data points represent mean ± 95% Confidence
Interval. One-way ANOVAs were performed with Bonferroni-corrected post t-tests. ⁄P < 0.01.
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Fig. 4. BEZ235 reduces hypoxia in vivo in the absence of vascular normalization. Xenograft tumors from the FaDu cell line with a stably expressed hypoxia-dependent
luciferase signal were grown in athymic nude mice. Mice were divided into cohorts of n = 4 mice per cohort. Tumors were treated for 7 days with BEZ235 at 0, 20 or 30 mg/kg.
(A) Hypoxia was monitored by bioluminescent imaging of the luciferase signal. Representative images and hypoxia measurements from FaDu tumors at day 7 treated with
BEZ235 at doses indicated show that the hypoxia signal is reduced with BEZ235 treatment. (B) Immunostaining for EF5 (green) in FaDu tumors independently confirmed the
reduction in hypoxia (10!magnification). (C) Perfusion as depicted by microbubbles (orange signal), was evaluated in the entire tumor at day 7 after treatment with BEZ235
as indicated. Increased perfusion, indicative of vascular normalization, was present in tumors treated with 20 mg/kg, but not 30 mg/kg, BEZ235. Columns, mean; bars, 95% CI.
(D) Evaluation of the effects of BEZ235 on pAKT, pS6 and the proliferation marker Ki-67 in FaDu tumors. Sections were stained with the indicated antibodies. Both doses of
BEZ235 reduced signaling through the PI3K/mTOR pathway, but only the higher dose (30 mg/kg) of BEZ235 reduced proliferation. Magnification as shown in image (E).
Columns, mean; bars, 95% CI, ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, over vehicle-treated control.
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overall perfusion consistent with the hypothesis that BEZ235 in-
duced decreased hypoxia due to reduced O2 consumption indepen-
dent of alterations in perfusion.
Altogether, our findings indicate that alterations to cellular O2
consumption could have a significant impact on tumor hypoxia,
in agreement with previous in vivo observations [3,12].
Discussion
In this study we show that pharmacological or genetic inhibi-
tion of the PI3K/mTOR pathway reduces mitochondrial O2 con-
sumption in a panel of cancer cell lines. As a consequence,
pharmacological inhibition of PI3K reduces hypoxia in spheroids
and tumor xenografts.
Several groups including our own have found that PI3K inhibi-
tion can lead to vascular normalization, correlating with decreased
hypoxia [14,38,43]. However, our findings here suggest that reduc-
ing cellular O2 consumption through PI3K inhibition can addition-
ally have a significant effect on hypoxia. It is likely that in vivo
changes in hypoxia mediated by PI3K inhibition result from a syn-
ergy of the increased blood flow and reduced respiration.
In agreement with our findings, reduced O2 consumption after
direct inhibition of the PI3K/mTOR pathway [26,32,35], or after
the withdrawal or inhibition of growth factors which act via the
pathway has been previously reported [3,32,49]. However there
is no consensus on how the pathway regulates oxidative respira-
tion. PI3K/AKT/mTOR signaling can be hypothesized to enhance
respiration throughmultiple mechanisms, including substrate gen-
eration, metabolite transport across the mitochondrial membrane
and activity of the mitochondrial machinery. While increased
mitochondria biogenesis is one means of generating increased oxi-
dative metabolism, we failed to detect evidence of a decrease in
overall mitochondria mass in treated cells with unchanged levels
of citrate synthase and increased levels of mitochondrial com-
plexes. However we did not examine mitochondrial numbers, mor-
phology or location. In our measurements of oxygen consumption,
excess pyruvate and glutamine were used to saturate the reaction,
removing substrate limitations. However, substrate availability
could still play a role in spheroids or in vivo, particularly through
glycolysis. Amounts of the glucose transporter GLUT1 may be re-
duced after PI3K/AKT/mTOR inhibition [7,11,36,39,48]. Localiza-
tion of hexokinase II to the mitochondria where it couples
glycolysis to ATP synthesis, enhancing glycolytic flux, is also re-
duced by mTOR and AKT inhibition [2,4,31].
Accessibility of ADP and ATP to the mitochondrial matrix could
be a point of regulation of mitochondrial oxygen consumption as
well. ADP and ATP enter the mitochondria through the outer mito-
chondrial membrane via the voltage dependent anion channel
(VDAC). ADP/ATP flow to and from mitochondrial ATP synthase is
essential to relieve the proton gradient set up by the ETC, enabling
electron transport and O2 consumption. Consistent with involve-
ment of ADP/ATP transport or turnover, mitochondrial hyperpolar-
ization, caused by a buildup of this gradient, has been reported in
both AKT- and mTOR complex 2-deficient cells and after treatment
with the mTOR inhibitor rapamycin [4,35]. It is possible that the
PI3K/mTOR pathway regulates VDAC. Localization of mTOR and
its target Ser473-phosphorylated AKT to VDAC1 are increased after
growth factor stimulation [4] and conductance through the chan-
nel is negatively regulated by the AKT target glycogen synthase ki-
nase 3b (GSK3b) [28,47,5].
Finally, F0F1-ATP synthase may be regulated by PI3K/AKT/mTOR
signaling. Active AKT interacts with ATP synthase [5,54] and its
subunits contain consensus sequences for AKT binding [26]. In
PTEN!/! cells, activated AKT binds the a and b subunits of ATP
synthase to stimulate activity [26]. Activated AKT may therefore
directly control the rate of ATP synthesis, and therefore oxygen
consumption, through phosphorylation of ATP synthase. ‘‘Further
work will be needed to elucidate the biochemical mechanisms that
lead to alterations in oxygen metabolism and to determine poten-
tial relationships to proliferation. Of course cell death itself could
decrease oxygen consumption. We attempted to control for toxic-
ity through normalization for cell death in tissue culture, by noting
that the effect is reversible in spheroids and that in vivo at the low-
er dose the extent of proliferation in similar to controls.’’
Decreased hypoxia in tumors treated with PI3K/mTOR inhibi-
tion would be expected to lead to increased sensitivity to radiation.
This expectation is confirmed since pharmacological inhibition of
PI3K, mTOR and dual PI3K/mTOR inhibition have all been reported
to increase sensitivity to DNA damaging agents in murine cancer
models [15,27,30,44]. We showed enhanced tumor growth delay
in response to radiation after treatment with BEZ325 correlating
with decreased hypoxia. However it is more difficult to determine
to what extent alleviation of hypoxia accounts for these results, be-
cause these inhibitors also sensitize cells to DNA damage under
oxic conditions. Inhibition of PI3K reduces DNA damage repair,
but BEZ235 also has off-target effects of inhibition of ATR and
DNA-PK [29]. Fokas et al. attempted to separate the effects on tu-
mor oxygenation from cell-specific effects by administering the
drug BEZ235 immediately before tumor radiation, when it still al-
tered tumor signaling but before the more prolonged changes of
hypoxia associated with extended preincubation had occurred.
This study however showed a substantial sensitization resulting
from the addition of BEZ235 to radiation. Approximately 1/3 of
the effect of sensitization resulted, suggesting that both alterations
in hypoxia and direct effects on tumor cell sensitization are at work
[14]. Nonetheless both mechanisms could contribute to radiosensi-
tization which could be of clinical significance.
In this study, we have demonstrated for the first time that inhi-
bition of the PI3K/mTOR pathway reduces cellular oxygen con-
sumption and leads to reoxygenation of tumor tissue
independent of vascular effects. In light of our findings, ongoing
clinical trials with PI3K/mTOR pathway inhibitors are likely to be
having substantial effects on tumor hypoxia. Because hypoxia
greatly reduces the efficacy of radiotherapy a combination of radi-
ation therapy with PI3K/mTOR inhibition may be beneficial.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc. 2014.02.
007.
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